S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.19 (+0.81%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.19 (+0.81%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.19 (+0.81%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.19 (+0.81%)
NFLX   187.44 (+0.58%)
NASDAQ:BYSI

BeyondSpring (BYSI) Stock Forecast, Price & News

$1.25
-0.04 (-3.10%)
(As of 05/23/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.24
$1.37
50-Day Range
$1.23
$2.66
52-Week Range
$1.20
$33.00
Volume
242,965 shs
Average Volume
440,874 shs
Market Capitalization
$48.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.21
30 days | 90 days | 365 days | Advanced Chart
Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

BeyondSpring logo

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Headlines

BeyondSpring Files 2021 Annual Report on Form 20-F
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BYSI
Employees
91
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.35 million
Book Value
$0.54 per share

Profitability

Net Income
$-64.18 million
Net Margins
-4,750.48%
Pretax Margin
-4,784.46%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$48.66 million
Optionable
Not Optionable

Company Calendar

Last Earnings
4/14/2022
Today
5/23/2022
Next Earnings (Estimated)
6/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.52 out of 5 stars

Medical Sector

1022nd out of 1,416 stocks

Pharmaceutical Preparations Industry

511th out of 677 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

Is BeyondSpring a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BeyondSpring stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BYSI, but not buy additional shares or sell existing shares.
View analyst ratings for BeyondSpring
or view top-rated stocks.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Wednesday, June 15th 2022.
View our earnings forecast for BeyondSpring
.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings data on Thursday, April, 14th. The company reported ($0.24) earnings per share for the quarter. The company earned $0.34 million during the quarter. BeyondSpring had a negative net margin of 4,750.48% and a negative trailing twelve-month return on equity of 144.52%.
View BeyondSpring's earnings history
.

What price target have analysts set for BYSI?

6 brokers have issued 12 month price targets for BeyondSpring's stock. Their forecasts range from $5.00 to $65.00. On average, they expect BeyondSpring's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 2,300.0% from the stock's current price.
View analysts' price targets for BeyondSpring
or view top-rated stocks among Wall Street analysts.

Who are BeyondSpring's key executives?
BeyondSpring's management team includes the following people:
  • Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 51)
  • Ms. Elizabeth Adkins Czerepak, Exec. VP & CFO (Age 66)
  • Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 78)
  • Dr. Ramon W. Mohanlal, Exec. VP of R&D, Chief Medical Officer and Director (Age 64)
  • Dr. Gordon L. Schooley, Chief Regulatory Officer (Age 75)
  • Mr. Linqing Jia, Co-Founder
  • Stephen Kilmer, Head of Investor Relations
  • Mr. Gregg Russo, Sr. VP of HR
What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

Who are BeyondSpring's major shareholders?

BeyondSpring's stock is owned by a variety of retail and institutional investors. Top institutional investors include Decheng Capital Management III Cayman LLC (12.74%), BlackRock Inc. (4.78%), State Street Corp (1.45%), Renaissance Technologies LLC (0.73%), Northern Trust Corp (0.42%) and BNP Paribas Arbitrage SA (0.34%).

Which institutional investors are selling BeyondSpring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Simplex Trading LLC, Jane Street Group LLC, Group One Trading L.P., and Northern Trust Corp.

Which institutional investors are buying BeyondSpring stock?

BYSI stock was bought by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, BlackRock Inc., Renaissance Technologies LLC, XTX Topco Ltd, State Street Corp, Acadian Asset Management LLC, Hennion & Walsh Asset Management Inc., and BNP Paribas Arbitrage SA.

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $1.25.

How much money does BeyondSpring make?

BeyondSpring has a market capitalization of $48.66 million and generates $1.35 million in revenue each year. The company earns $-64.18 million in net income (profit) each year or ($1.640010) on an earnings per share basis.

How many employees does BeyondSpring have?

BeyondSpring employs 91 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at (646) 305-6387, via email at [email protected], or via fax at 1-646-882-4228.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.